Status:
COMPLETED
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Eligibility:
All Genders
Up to 15 years
Brief Summary
This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors le...
Detailed Description
PRIMARY OBJECTIVES: I. Describe the pharmacokinetics of ch14.18 (monoclonal antibody Ch14.18) in children with high-risk neuroblastoma. II. Quantify the degree of inter-patient and intra-patient var...
Eligibility Criteria
Inclusion
- Diagnosis of high-risk neuroblastoma
- Enrolled on the COG protocol ANBL0032 or ANBL0931 and eligible to receive ch14.18 according to the criteria on these primary treatment protocols
- Parental informed consent and verbal assent of the subject when appropriate
Exclusion
- Prior testing demonstrating the presence of HACA
- Anaphylactic reaction to ch14.18 on a prior treatment cycle
Key Trial Info
Start Date :
May 26 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01418495
Start Date
May 26 2011
Last Update
October 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104